Tuesday, 26 April 2016

Study Shows Potential of Novel Compound to Treat Secondary Progressive Multiple Sclerosis

Source Neurology Advisor:


VANCOUVER, British Columbia — For the treatment of secondary-progressive multiple sclerosis (SPMS), NDC-1308−a small molecule that activates intracellular pathways for oligodendrocyte progenitor cell (OPC) differentiation−showed favorable pharmacokinetic properties and was safe in a mice study.  Read on.